Search Results for keywords:"hearing request"

Fisher Clinical Services, Inc. has applied to the Drug Enforcement Administration to be registered as an importer of certain controlled substances. The purpose of this registration is solely for use in clinical trials, and not for the commercial sale of the substances. The public can submit comments or request a hearing about this application until April 14, 2025. Comments must be submitted electronically, and hearings can be requested in writing, with specific addresses provided for these submissions.

Patheon Pharmaceuticals Inc. has applied to the Drug Enforcement Administration to become a registered bulk manufacturer of certain controlled substances. The company plans to use these substances as Active Pharmaceutical Ingredients in FDA-approved medications. Anybody interested can submit comments or objections electronically by May 12, 2025, through the Federal eRulemaking Portal. Requests for a hearing regarding this application are also due by the same date.

The Securities and Exchange Commission (SEC) has issued a notice regarding an application for an exemption under the Investment Company Act of 1940. The application involves the Optimize Growth Equity Fund, Optimize Premium Yield Fund, and Optimize Wealth Management Inc., seeking permission for certain registered closed-end investment companies to make repurchase offers monthly. If someone wishes to contest this application or request a hearing, they must submit their request to the SEC by May 6, 2025. The application details and conditions are available through the SEC's EDGAR system.

Indivior Inc. has applied to the Drug Enforcement Administration (DEA) to be registered as an importer of certain controlled substances. They intend to import these substances in limited quantities for use in research, clinical trials, and for developing the manufacturing process of dosage forms. Comments or objections regarding this application can be submitted electronically by April 7, 2025, and requests for a hearing can also be made by that date. The DEA requires that comments be submitted through their online portal.

In a notice from the Securities and Exchange Commission (SEC), an application was submitted under the Investment Company Act of 1940. The applicants, including Privacore PCAAM Alternative Income Fund and others, are seeking exemptions to allow certain investment companies to issue multiple share classes with asset-based distribution or service fees and early withdrawal charges. A hearing on the application may occur if requested by December 23, 2024. Public comments and hearing requests can be submitted via email, and further information is available on the SEC's EDGAR system.

The Drug Enforcement Administration (DEA) has announced that Siegfried USA, LLC, located in Pennsville, New Jersey, has applied to be registered as a bulk manufacturer of certain controlled substances. Interested parties, including registered manufacturers of these substances, can submit comments or objections electronically by March 24, 2025. They can also request a hearing on the application by the same date. This registration will allow Siegfried USA to produce these substances in bulk for sale.

Patheon API Manufacturing, Inc. has applied to the Drug Enforcement Administration (DEA) to become a registered bulk manufacturer of certain controlled substances. The company intends to produce these substances as Active Pharmaceutical Ingredients (APIs) for its customers, specifically focusing on synthetic tetrahydrocannabinols. The public, including existing manufacturers and applicants, may submit comments or request a hearing on this application by April 20, 2021.

The Securities and Exchange Commission (SEC) is considering an application from several investment companies and entities for an order that would allow them to make certain joint investments that are usually not allowed under existing rules. The order would permit closed-end management investment companies and business development companies to work together on investments in portfolio companies. This application was submitted in July 2024 and has been revised multiple times, most recently on March 3, 2025. Interested individuals can request a hearing regarding this matter by contacting the SEC and the involved parties by April 7, 2025.

The Securities and Exchange Commission (SEC) has published a notice regarding an application for an order under the Investment Company Act of 1940. The order would grant exemptions from certain sections of the Act and a rule under it, allowing ActiveShares ETFs to issue and redeem shares in large batches, and facilitate market transactions at negotiated prices. The application involves the ActiveShares ETF Trust, Legg Mason Partners Fund Advisor, LLC, and Legg Mason Investor Services, LLC, seeking relief consistent with a prior order. The SEC will issue the order unless someone requests a hearing by February 8, 2021, by contacting the SEC via email.

Siegfried USA, LLC, located in New Jersey, has submitted an application to become an importer of specific controlled substances, as noted by the Drug Enforcement Administration (DEA). The company plans to import these substances to create active pharmaceutical ingredients for its clients, specifically using Phenylacetone to produce Amphetamine. Comments or objections regarding this application are invited by March 18, 2021, and requests for a hearing can also be made by this date. Final permit approval will align with conditions outlined under the relevant U.S. Code and does not permit the commercial import of drug forms approved or non-approved by the Food and Drug Administration (FDA).